Association between aspartic acid repeat polymorphism of the asporin gene and risk of knee osteoarthritis: A systematic review and meta-analysis

Abstract

ObjectiveStudies have assessed the association between aspartic acid (D)-repeat polymorphism in the gene encoding Asporin (ASPN) and knee osteoarthritis (KOA) risk, but the results were inconclusive and contradictory. Therefore, we performed a meta-analysis to investigate the association between ASPN gene D-repeat polymorphism and KOA risk.MethodsEligible studies were identified by searching several electronic databases for relevant reports published before September 2016. The pooled odds ratios (ORs) for the association between ASPN polymorphism and KOA and their corresponding 95% confidence intervals (CIs) were estimated using the random- or fixed-effect model.ResultsA total of eleven case-control studies in ten publications with 4610 KOA cases and 3621 controls were included for the ASPN D-repeat polymorphism. Overall, no significant association was detected for D14 allele carrier (D14 vs. D13: OR = 1.10, 95% CI = 0.90–1.36, p = 0.32). Meta-analysis of D14 vs. other alleles and D13 vs. other alleles showed the same pattern of KOA association as the D14 vs. D13 (OR = 1.30, 95% CI = 1.00–1.70, p = 0.06; OR = 0.93, 95% CI = 0.82–1.06, p = 0.33, respectively). Also, in the stratified analysis by ethnicity, no significant association of this polymorphism with risk of KOA was found in the European and Asians populations (OR = 1.05, 95% CI = 0.91–1.21, p = 0.49; OR = 0.98, 95% CI = 0.78–1.23, p = 0.88, respectively).ConclusionsThe present meta-analysis suggests that the ASPN D-repeat polymorphism is not associated with an increased KOA risk. However, future large studies with gene–gene and gene–environment interactions are needed to validate these findings.Level of evidenceLevel III diagnostic study.

Association of Interleukin-10 -1082 a/G (Rs1800896) Polymorphism With Susceptibility to Gastric Cancer: Meta-Analysis of 6,101 Cases and 8,557 Controls

“…After reading the full texts of the remaining 37 articles, we found one article had not sufficient data of genotype for calculating OR and 95% CI, four articles were meta-analyses, and two articles were reviews. Finally, a total of 30 studies (4)(5)(6)(7)(10)(11)(12)(13)(14)(16)(17)(18)(19)(20)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39) published from 2002 and 2015 with 6,101 cases and 8,557 controls met our inclusion criteria. The main characteristics of these studies were listed in TABLE 1.…”

“…The Q-statistic and the I 2 -statistic were used to assess the heterogeneity between studies in the meta-analysis. I 2 was a value describe the degree of heterogeneity between studies, where 0-25% indicated no observed heterogeneity and larger values showed increasing heterogeneity, with 25%-50% regarded as low, 50%-75% as moderate, and 75%-100% as high (18,19) . A P-value greater than 0.10 for the Q-statistic indicates a lack of heterogeneity between studies, so the pooled OR estimate of the included studies was calculated by the fixed-effects model (MantelHaenszel method) (20) .…”

“…Thus, one of the most important goals of the meta-analysis is to identify the source of heterogeneity (56) . Basically, between-studies variability and variability due to sampling error are main sources of heterogeneity in a set of studies in a meta-analysis (19,31,55,56) . The between-study heterogeneity in the current meta-analysis existed in overall under all genetic models and subgroup analyses in Asians.…”

Vasohibin 1 inhibits Adriamycin resistance in osteosarcoma cells via the protein kinase B signaling pathway

“…Surgery combined with adjuvant chemotherapy is currently the standard treatment for osteosarcoma (1). In recent years, although a great deal of effort has been made toward improving chemotherapy regimens, the overall prognosis remains poor and much of this may be attributed to drug resistance (2).…”

“…Osteosarcoma is the most common malignant tumor of the bone and remains the second leading cause of cancer-associated mortality in adolescents globally at present (1). Surgery combined with adjuvant chemotherapy is currently the standard treatment for osteosarcoma (1).…”